Anadys Pharmaceuticals develops novel therapeutics for the treatment of chronic hepatitis C viral infections.
Anadys Pharmaceuticals is a biopharmaceutical company that develops novel therapeutics for the treatment of chronic hepatitis C viral infections.The company focuses on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7 or TLR7.Anadys Pharmaceuticals was founded in 1992 and is headquartered in San Diego, California. As of November 22, 2011, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 11, 2005 | Private Equity(PE) | $71.30M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lotus BioScience Ventures | — | Private Equity(PE) |
Coastview Capital | — | Private Equity(PE) |